S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
US consumer sentiment falls slightly as outlook for inflation worsens
Faced with possibly paying for news, Google removes links to California news sites for some users
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
US consumer sentiment falls slightly as outlook for inflation worsens
Faced with possibly paying for news, Google removes links to California news sites for some users
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
US consumer sentiment falls slightly as outlook for inflation worsens
Faced with possibly paying for news, Google removes links to California news sites for some users
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
How major US stock indexes fared Friday, 4/12/2024
US consumer sentiment falls slightly as outlook for inflation worsens
Faced with possibly paying for news, Google removes links to California news sites for some users
NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Price, News & Analysis

$0.74
-0.01 (-1.32%)
(As of 04/12/2024 ET)
Today's Range
$0.74
$0.76
50-Day Range
$0.73
$1.50
52-Week Range
$0.72
$7.20
Volume
42,886 shs
Average Volume
104,919 shs
Market Capitalization
$5.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Ensysce Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
839.7% Upside
$7.00 Price Target
Short Interest
Healthy
0.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.06mentions of Ensysce Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.50) to ($2.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

ENSC stock logo

About Ensysce Biosciences Stock (NASDAQ:ENSC)

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.

ENSC Stock Price History

ENSC Stock News Headlines

These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
ENSC Striding Toward Opioid Replacement
ENSC: Investors Should Pay Attention
These AI trades triggered this morning (545% return)
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
ENSC Announces Major FDA Designation
Ensysce Biosciences Issues 2024 Shareholder Letter
See More Headlines
Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/13/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ENSC
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+839.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,610,000.00
Net Margins
-476.29%
Pretax Margin
-476.29%

Debt

Sales & Book Value

Annual Sales
$2.23 million
Book Value
($0.21) per share

Miscellaneous

Free Float
3,467,000
Market Cap
$5.46 million
Optionable
Not Optionable
Beta
0.77
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. D. Lynn Kirkpatrick Ph.D. (Age 67)
    President, CEO & Director
    Comp: $414.77k
  • Mr. Geoffrey Birkett (Age 61)
    Chief Commercial Officer
    Comp: $322k
  • Dr. Jeffrey Millard Ph.d. (Age 48)
    Chief Operating Officer
  • Dr. William K. Schmidt Ph.D. (Age 73)
    Chairman of Clinical Advisory Board & Chief Medical Officer
  • Dr. Linda Pestano Ph.D. (Age 54)
    Chief Development Officer

ENSC Stock Analysis - Frequently Asked Questions

Should I buy or sell Ensysce Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ENSC shares.
View ENSC analyst ratings
or view top-rated stocks.

What is Ensysce Biosciences' stock price target for 2024?

1 equities research analysts have issued 12-month price objectives for Ensysce Biosciences' shares. Their ENSC share price targets range from $7.00 to $7.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 839.7% from the stock's current price.
View analysts price targets for ENSC
or view top-rated stocks among Wall Street analysts.

How have ENSC shares performed in 2024?

Ensysce Biosciences' stock was trading at $1.06 at the beginning of the year. Since then, ENSC shares have decreased by 29.7% and is now trading at $0.7450.
View the best growth stocks for 2024 here
.

Are investors shorting Ensysce Biosciences?

Ensysce Biosciences saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 17,500 shares, a decline of 69.0% from the March 15th total of 56,500 shares. Based on an average daily trading volume, of 1,450,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.6% of the shares of the company are short sold.
View Ensysce Biosciences' Short Interest
.

When is Ensysce Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ENSC earnings forecast
.

When did Ensysce Biosciences' stock split?

Ensysce Biosciences shares reverse split before market open on Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Ensysce Biosciences?

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENSC) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners